×
About 14,580 results

ALLMedicine™ Myelodysplastic Syndrome Center

Research & Reviews  7,061 results

Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute...
https://doi.org/10.1111/ejh.13631
European Journal of Haematology; Tey A, Shaw B et. al.

Apr 8th, 2021 - The rate of invasive fungal infection (IFI) in patients with myelodysplasia (MDS) and acute myeloid leukaemia (AML) receiving 5-azacytidine is incompletely defined and published recommendations for mold-active fungal prophylaxis in such patients v...

Autoimmune manifestations associated with myelodysplastic syndrome predict a poor progn...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021323
Medicine Arinobu Y, Kashiwado Y et. al.

Mar 31st, 2021 - We evaluated the clinical characteristics of autoimmune manifestations (AIMs) associated with myelodysplastic syndrome (MDS) to elucidate whether AIMs impacted MDS outcomes in Japan.This retrospective study including 61 patients who received a new...

Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after all...
https://doi.org/10.1111/ejh.13628
European Journal of Haematology; Drozd-Sokołowska J, Karakulska-Prystupiuk E et. al.

Mar 25th, 2021 - Relapse of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) belongs to the major causes of treatment failure. Retrospective multicenter analysis of patients diagno...

A novel germline GATA2 frameshift mutation with a premature stop codon in a family with...
https://doi.org/10.1007/s12185-021-03130-w 10.1002/cam4.384 10.1182/blood-2013-07-515528 10.1053/j.seminhematol.2017.05.002 10.1007/s12185-017-2285-2 10.1034/j.1600-0609.2003.00039.x 10.1182/blood-2011-05-356352 10.1002/iub.2188 10.1002/dvdy.22373 10.1111/gtc.12705 10.1016/j.bbmt.2014.08.004
International Journal of Hematology; Nakazawa H, Yamaguchi T et. al.

Mar 24th, 2021 - GATA2 is a zinc-finger transcription factor regulating early hematopoiesis and developmental processes. Heterozygous germline mutations in GATA2 underlie a pleiotropic autosomal dominant disorder, GATA2 deficiency syndrome. The wide spectrum of it...

Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patie...
https://doi.org/10.1007/s00277-021-04495-y 10.1182/blood.V89.6.2079 10.1016/S0092-8674(04)00343-5 10.1007/s12185-008-0118-z 10.1016/j.leukres.2017.01.033 10.7326/M19-0916 10.1111/j.1365-2141.2007.06695.x 10.3324/haematol.12759 10.1111/j.1365-2141.2011.08749.x 10.1016/j.leukres.2018.12.001 10.1002/ajh.20980 10.1111/bjh.12368 10.1053/euhj.2001.2822 10.1002/jmri.20566 10.1007/s00330-018-5783-6 10.1002/mrm.22410 10.1016/j.ijcard.2014.09.139 10.1093/ehjci/jex012 10.1002/jmri.25450 10.1136/hrt.2008.156497 10.1002/jmri.21781 10.3324/haematol.2010.025510 10.1097/00000421-198212000-00014 10.1111/j.1600-0609.2005.00587.x 10.1002/nbm.1121 10.1016/j.mri.2008.06.004 10.1002/nbm.1382 10.1161/CIRCULATIONAHA.110.007641 10.1002/jmri.22417 10.1111/bjh.12296 10.1056/NEJM200008033430503 10.1161/HYPERTENSIONAHA.111.198028 10.1002/jmri.21704 10.1081/JCMR-200053630 10.1161/CIRCULATIONAHA.106.180199 10.2459/JCM.0b013e3282f20847 10.1161/CIRCULATIONAHA.109.192064 10.1016/0895-4356(94)90129-5 10.1371/journal.pone.0023109 10.1007/s12185-017-2367-1 10.1586/17474086.2013.814456 10.1161/01.CIR.88.3.1127 10.1111/bjh.12557 10.1016/j.leukres.2019.106170
Annals of Hematology; Pepe A, Rizzo M et. al.

Mar 20th, 2021 - We prospectively evaluated changes in cardiac and hepatic iron overload (IO) and in morpho-functional cardiac parameters and myocardial fibrosis by magnetic resonance imaging (MRI) in patients with low-risk and intermediate-1-risk myelodysplastic ...

see more →

Guidelines  9 results

FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome
https://www.healio.com/hematology-oncology/myeloproliferative-neoplasms/news/online/%7B1dd18005-dfc3-4413-ac65-6a84a3edc248%7D/fda-grants-fast-track-orphan-drug-designations-to-apr-246-for-myelodysplastic-syndrome

Apr 15th, 2019 - The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations. The agency also granted orphan drug designation to APR-246 (Aprea Therapeutics) for treatment of myelodysplasti...

Primary prophylaxis of invasive fungal infections in patients with haematological malig...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754425
Annals of Hematology; Mellinghoff SC, Panse J et. al.

Dec 8th, 2017 - Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) a...

Therapy-Related AML and MDS: Who Really Has It?
https://www.hematology.org/Thehematologist/Features/4147.aspx

Jun 4th, 2015 - Most of our knowledge of a relationship between exposure to cancer therapy and developing acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) comes from epidemiological studies. So it is important to remember epidemiology deals with ass...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 27th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

see more →

Drugs  49 results see all →

Clinicaltrials.gov  7,277 results

Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute...
https://doi.org/10.1111/ejh.13631
European Journal of Haematology; Tey A, Shaw B et. al.

Apr 8th, 2021 - The rate of invasive fungal infection (IFI) in patients with myelodysplasia (MDS) and acute myeloid leukaemia (AML) receiving 5-azacytidine is incompletely defined and published recommendations for mold-active fungal prophylaxis in such patients v...

Autoimmune manifestations associated with myelodysplastic syndrome predict a poor progn...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021323
Medicine Arinobu Y, Kashiwado Y et. al.

Mar 31st, 2021 - We evaluated the clinical characteristics of autoimmune manifestations (AIMs) associated with myelodysplastic syndrome (MDS) to elucidate whether AIMs impacted MDS outcomes in Japan.This retrospective study including 61 patients who received a new...

Myelodysplastic syndromes - Diagnosis and treatment - Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/diagnosis-treatment/drc-20366980

Mar 29th, 2021 - Diagnosis Bone marrow exam Open pop-up dialog box Close Bone marrow exam Bone marrow exam In a bone marrow aspiration, a doctor or nurse uses a thin needle to remove a small amount of liquid bone marrow, usually from a spot in the back of your hip...

Azacitidine - azacitidine injection, powder, lyophilized, for solution-BluePoint Laboratories
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a

Mar 28th, 2021 - Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if a...

Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after all...
https://doi.org/10.1111/ejh.13628
European Journal of Haematology; Drozd-Sokołowska J, Karakulska-Prystupiuk E et. al.

Mar 25th, 2021 - Relapse of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) belongs to the major causes of treatment failure. Retrospective multicenter analysis of patients diagno...

see more →

News  181 results

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: High-Risk Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943966

Feb 2nd, 2021 - Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. MDS may involve one, two, or three myeloid hematopoiesis cell lineages — erythrocytic, granulocytic, megak...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

In MDS, Transplant Ups Survival in Elderly and May Be Reimbursed
https://www.medscape.com/viewarticle/942069

Dec 3rd, 2020 - New results suggest that allogeneic hematopoietic cell transplantation (HCT), which is typically reserved for younger patients, may well be offered to older patients with advanced myelodysplastic syndrome (MDS). In patients with a median age of 66...

see more →

Patient Education  3 results see all →